Welcome to our dedicated page for 111 American Depositary Shares news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 American Depositary Shares stock.
111, Inc. (NASDAQ: YI) operates an integrated online and offline platform in the healthcare market in China. The company operates through two segments: B2B and B2C. 111, Inc. sells medical and wellness products through online retail, wholesale and retail pharmacies, and offline retail pharmacies. The company also provides value-added services like online consultation and e-prescription services.
The company's product portfolio includes:
- Prescription and OTC Drugs: Western and traditional Chinese medicinal drugs.
- Nutritional Supplements: Vitamins and dietary products.
- Contact Lenses: A variety of contact lenses.
- Medical Supplies and Devices: Bandages, thermometers, and more.
- Personal Care Products: Skin care, birth control, and sexual wellness products.
- Baby Products: A range of baby care products.
111, Inc. also manages an online marketplace enabling third-party sellers to reach pharmacies. The company’s online loan application services support clients of 1 Drug Mall. 111, Inc. derives a majority of its revenue from the B2B segment.
Recent achievements include:
- Earnings Call Announcements: The company recently announced its Q3 2023 financial results showing net revenue growth of 9.5% year-over-year despite challenges in the macro-economy and retail pharmacy business.
- Digital Innovations: The 111 technology team secured three patents and won several prestigious awards in 2023 for their contributions to digital healthcare.
- Strategic Partnerships: 111, Inc. entered into a strategic direct supply partnership with Beijing Scrianen Pharmaceutical Co., Ltd., enhancing their collaboration to increase drug accessibility.
The company’s financial condition shows a strong trajectory with significant investments in digitalization and operational efficiency, ensuring sustainability and growth. The robust relationships with over 500 pharmaceutical partners and operational optimization for 450,000 retail pharmacies demonstrate their market leadership.
For more information on 111, please visit: http://ir.111.com.cn/.
111, Inc. (NASDAQ: YI) reported Q3 2024 financial results showing maintained operational profitability for the third consecutive quarter. Net revenues were RMB3.6 billion (US$513.1 million), relatively flat year-over-year. The company achieved income from operations of RMB2.4 million, compared to a loss of RMB80.4 million in the same quarter last year. Operating expenses decreased by 23.2% to RMB208.2 million, representing 5.8% of net revenues, an improvement of 160 basis points. The company maintained positive operating cash flow for three consecutive quarters, with Q3 generating RMB109.9 million.
111, Inc. (NASDAQ: YI) has announced its participation in a fireside chat with Water Tower Research on December 6, 2024 at 11:00 a.m. ET. The company's Co-Founder, Chairman, and CEO, Junling Liu, will discuss Q3 2024 earnings (to be reported on November 27, 2024), along with challenges, opportunities, and NASDAQ share price compliance issues. The tech-enabled healthcare platform company, focused on digitally transforming China's healthcare value chain, will host this listen-only event with WTR's senior research analyst Robert Sassoon. A replay will be available on 111's investor relations website.
111, Inc. (NASDAQ: YI) has rescheduled its Q3 2024 unaudited financial results announcement from November 28 to November 27, 2024, before U.S. market opens. The management team will host an earnings conference call at 7:30 AM U.S. Eastern Time (8:30 PM Beijing Time) on the same day. The company has provided registration details for the conference call and webcast, with replay access available until December 4, 2024.
111, Inc. (NASDAQ: YI) announced changes to its Board of Directors on November 4, 2024. Dr. Leon Lian Yong Chen has resigned from his director position for personal reasons, effective immediately. The company has appointed Mr. Yang "Luke" Chen, currently serving as Senior Finance Executive, as the new director. Dr. Chen had served on the board since May 2019. The company's Executive Chairman, Mr. Gang Yu, expressed gratitude for Dr. Chen's contributions and welcomed Luke Chen, highlighting his financial expertise and understanding of the business as valuable assets for the company's strategic initiatives.
111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform in China, will join a fireside chat with Robert Sassoon from Water Tower Research on October 30, 2024 at 12:00 p.m. ET. Dr. Gang Yu, Co-Founder and Executive Chairman, will discuss the company's logistics network, including its fulfillment centers, operating models, and technological innovations. He will also cover the expansion plans. To register for this listen-only event, visit the provided link. A replay will be available under 'Events' on the company's investor relations website.
111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, has announced it will report its unaudited financial results for the third quarter ended September 30, 2024, before the U.S. market opens on Thursday, November 28, 2024. The company's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on the same day.
Participants are required to register in advance using the provided link. Upon registration, they will receive dial-in information, including a passcode and unique access PIN. A live and archived webcast of the conference call will be available on the company's website. Additionally, a telephone replay of the call will be accessible until December 5, 2024, with dial-in numbers provided for China, United States, and international callers.
111, Inc. (NASDAQ: YI) has expanded its national supply chain network with new fulfillment centers in Guangzhou and Wuhan. These additions bring the total number of centers to 13 across China, enhancing the company's warehousing and distribution capabilities. The new centers utilize an innovative operational model that reduces costs and improves efficiency, enabling 24-hour deliveries in most South and Central China markets.
The expansion strengthens 111's nationwide logistics network, 'Kunpeng,' which has reduced delivery costs by 15% and damage rates by 55%. The company's smart supply chain management systems, powered by over 30 self-developed technologies, support these operations. 111's virtual pharmacy network now serves approximately 470,000 pharmacies and partners with over 500 global pharmaceutical companies and 4,500 distributors.
111, Inc. (NASDAQ: YI), a tech-enabled healthcare platform company in China, has received a notification from Nasdaq on September 26, 2024. The notice states that for the last 30 consecutive business days, the closing bid price of the company's American depositary shares (ADSs) was below the minimum requirement of $1.00 per share, as per Nasdaq Listing Rule 5450(a)(1).
The company has been granted a 180-day compliance period, until March 24, 2025, to regain compliance. If the closing bid price of YI's ADSs reaches $1.00 or higher for at least ten consecutive business days during this period, Nasdaq will confirm compliance in writing. If YI fails to regain compliance by March 24, 2025, it may be eligible for an additional 180-day compliance period, subject to Nasdaq staff determination.
111, Inc. assures that its business operations are not affected by this notification and intends to monitor the closing bid price of its ADSs, taking reasonable measures to regain compliance with Nasdaq's minimum bid price requirement.
111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform in China, announced that its co-founders, Dr. Gang Yu and Mr. Junling Liu, have begun purchasing company shares from their personal funds. The purchases will be made on the open market at prevailing prices. The co-founders currently own 42.7% of the company's total issued share capital.
111 reported strong financial performance in Q2 2024, achieving operational profitability for the second consecutive quarter. Income from operations reached RMB3.3 million (US$0.5 million), compared to a loss of RMB41.4 million in Q2 2023. Non-GAAP income from operations was RMB8.5 million (US$1.2 million). The company also reported positive operating cash flow.
Additionally, 111 acquired four new patents, bringing its total to 28, enhancing its competitive advantages in operational efficiency and supporting long-term growth prospects.
111, Inc. (NASDAQ: YI) announced its Q2 2024 financial results, highlighting maintained operational profitability for the second consecutive quarter. Key points include:
- Net revenues were RMB3.4 billion (US$471.2 million), down 1.5% YoY
- Income from operations was RMB3.3 million, compared to a loss of RMB41.4 million in Q2 2023
- Operating expenses decreased 18.1% YoY to RMB204.3 million
- Operating expenses as a percentage of net revenues decreased by 120 basis points to 6.0%
- Positive operating cash flow for two consecutive quarters
- Non-GAAP income from operations was RMB8.5 million
The company emphasized improved operational efficiency, strategic initiatives, and focus on digital capabilities to drive growth in the healthcare e-commerce sector.
FAQ
What is the current stock price of 111 American Depositary Shares (YI)?
What is the market cap of 111 American Depositary Shares (YI)?
What is 111, Inc.?
What products does 111, Inc. offer?
How does 111, Inc. generate revenue?
What recent achievements has 111, Inc. made?
Who are 111, Inc.’s strategic partners?
What are the key services provided by 111, Inc.?
What is the financial condition of 111, Inc.?
How does 111, Inc. leverage digital technology?
What is the significance of the partnership with Scrianen?
Where can I find more information about 111, Inc.?
